BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company’s Board of Directors. “We are thrilled to welcome Keith to the X4 Board of Directors,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.

2023年10月18日波士顿（GLOBE NEWSWIRE）-X4制药公司（纳斯达克股票代码：XFOR）是一家致力于改善免疫系统罕见疾病患者生活的公司，今天宣布任命R.Keith Woods为公司董事会独立董事。X4制药公司总裁兼首席执行官Paula Ragan博士说：“我们很高兴欢迎Keith加入X4董事会。”。

“With his broad and deep experience in commercialization, international operations, supply chain, and business strategy, as well as his recent successful global launch of a rare disease product, we believe it is a great time for him to be joining X4 as a director and that his skillset will complement the strengths and expertise of our Board.” Mr.

“凭借他在商业化，国际运营，供应链和商业战略方面的广泛而深刻的经验，以及他最近在全球成功推出的罕见疾病产品，我们相信现在是他加入X4担任董事的好时机了，他的技能将补充我们董事会的优势和专业知识。”先生。

Woods brings more than 30 years of life science experience spanning sales, global operations, supply chain, business strategy, and commercialization to the X4 Board. Most recently, he served as Chief Operating Officer of argenx, a company focused on rare diseases, where he helped lead argenx through its successful transition from an R&D organization to a global commercial organization.

伍兹为X4董事会带来了30多年的生命科学经验，包括销售，全球运营，供应链，业务战略和商业化。最近，他担任argenx（一家专注于罕见病的公司）的首席运营官，在那里他帮助argenx成功地从研发组织过渡到全球商业组织。

Following his retirement from argenx, Mr. Woods continues to serve as an advisor to the argenx Board of Directors. Mr. Woods previously served in a variety of roles at Alexion Pharmaceuticals, including Vice President and Managing Director of Alexion UK, overseeing all aspects of Alexion’s UK business, and Vice President, U.S.

在从argenx退休后，伍兹先生继续担任argenx董事会的顾问。伍兹先生曾在Alexion Pharmaceuticals担任各种职位，包括英国Alexion的副总裁和总经理，负责监督Alexion英国业务的各个方面，以及美国副总裁。

Commercial Operations, ending his tenure there as Senior Vice President of North America Business Operations. Prior to that, he spent more than two decades in roles of increasing responsibility at Roche, Amgen, and Eisai, where he gained valuable experience crafting effective commercial strategies a.

商业运营，结束他在北美业务运营高级副总裁的任期。在此之前，他在罗氏，安进和卫材担任越来越重要的角色二十多年，在那里他获得了制定有效商业战略的宝贵经验a。